Adrian Kobe

Adrian Kobe

Auto-generated profile, based on publicly available information

Adrian Kobe

Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Radiology
Verified
Journal Article
Closed access
ANArash Najafi
Arash Najafi
MAMarc Al Ahmar
Marc Al Ahmar
Baptiste BonnetBaptiste Bonnet
Baptiste Bonnet
ADAlexandre DELPLA
Alexandre DELPLA
AKAdrian Kobe
Adrian Kobe
LTLambros Tselikas
Lambros Tselikas
For CT-guided percutaneous lung biopsy, positioning biopsy-side down, needle removal during expiration, autologous blood patch sealing, rapid rollover, and pleural patching, or PEARL, reduced pneum... Background Percutaneous CT-guided biopsy of lung nodules is an established method with high diagnostic accuracy but a high rate of pneumothorax and chest tube insertion compared with endobronchial ...

16 March 2023 in European Journal of Cancer
Verified
Journal Article
Open access
FDFrederic Deschamps
Frederic Deschamps
LTLambros Tselikas
Lambros Tselikas
SYSteven Yevich
Steven Yevich
BBBaptiste Bonnet
Baptiste Bonnet
CRCharles Roux
Charles Roux
TBThierry de Baere
Thierry de Baere
To report efficacy and safety of percutaneous electrochemotherapy (ECT) in patients with radiotherapy-resistant metastatic epidural spinal cord compression (MESCC). This retrospective study analyzed all consecutive patients treated with bleomycin-based ECT between February-2020 and September-2022 in a single tertiary referral cancer center. Changes in pain were evaluated with the Numerical Rating Score (NRS), in neurological deficit with the Neurological Deficit Scale, and changes in epidural spinal cord compression were evaluated with the epidural spinal cord compression scale (ESCCS) using an MRI. Forty consecutive solid tumour patients with previously radiated MESCC and no effective systemic treatment options were eligible. With a median follow-up of 5.1 months [1-19.1], toxicities were temporary acute radicular pain (25%), prolonged radicular hypoesthesia (10%), and paraplegia (7.5%). At 1 month, pain was significantly improved over baseline (median NRS: 1.0 [0-8] versus 7.0 [1.0-10], P < .001) and neurological benefits were considered as marked (28%), moderate (28%), stable (38%), or worse (8%). Three-month follow-up (21 patients) confirmed improved over baseline (median NRS: 2.0 [0-8] versus 6.0 [1.0-10], P < .001) and neurological benefits were considered as marked (38%), moderate (19%), stable (33.5%), and worse (9.5%). One-month post-treatment MRI (35 patients) demonstrated complete response in 46% of patients by ESCCS, partial response in 31%, stable disease in 23%, and no patients with progressive disease. Three-month post-treatment MRI (21 patients) demonstrated complete response in 28.5%, partial response in 38%, stable disease in 24%, and progressive disease in 9.5%. This study provides the first evidence that ECT can rescue radiotherapy-resistant MESCC.

1 January 2020 in European Journal of Radiology Open
Verified
Journal Article
Open access
VMVictor Mergen
Victor Mergen
AKAdrian Kobe
Adrian Kobe
CBChristian Blüthgen
Christian Blüthgen
AEAndré Euler
André Euler
TFThomas Flohr
Thomas Flohr
MEMatthias Eberhard
Matthias Eberhard
To demonstrate the first experience of a deep learning-based algorithm for automatic quantification of lung parenchymal abnormalities in chest CT of COVID-19 patients and to correlate quantitative results with clinical and laboratory parameters. We retrospectively included 60 consecutive patients (mean age, 61 ± 12 years; 18 females) with proven COVID-19 infection undergoing chest CT between March and May 2020. Clinical and laboratory data (within 24 h before/after chest CT) were recorded. Prototype software using a deep learning algorithm was applied for automatic segmentation and quantification of lung opacities. Percentage of opacity (PO, ground-glass and consolidations) and percentage of high opacity (PHO, consolidations), were defined as 100 times the volume of segmented abnormalities divided by the volume of the lung mask. Automatic CT analysis of the lung was feasible in all patients (n = 60). The median time to accomplish automatic evaluation was 120 s (IQR: 118–128 s). In four cases (7 %), manual corrections were necessary. Patients with need for mechanical ventilation had a significantly higher PO (median 44 %, IQR: 23–58 % versus 13 %, IQR: 10–24 %; p = 0.001) and PHO (median: 11 %, IQR: 6–21 % versus 3%, IQR: 2–7 %, p = 0.002) compared to those without. The PO and PHO moderately correlated with c-reactive protein (r = 0.49−0.60, both p < 0.001) and leucocyte count (r = 0.30−0.40, both p = 0.05). PO had a negative correlation with SO2 (r=−0.50, p = 0.001). Preliminary experience indicates the feasibility of a rapid, automatic quantification tool of lung parenchymal abnormalities in COVID-19 patients using deep learning, with results correlating with laboratory and clinical parameters.

30 August 2021 in European Journal of Radiology Open
Verified
Journal Article
Open access
AKAdrian Kobe
Adrian Kobe
JZJuliana Zgraggen
Juliana Zgraggen
FMFlorian Messmer
Florian Messmer
GPGilbert Puippe
Gilbert Puippe
TSThomas Sartoretti
Thomas Sartoretti
MMManoj Mannil
Manoj Mannil
To investigate the potential of texture analysis and machine learning to predict treatment response to transarterial radioembolization (TARE) on pre-interventional cone-beam computed tomography (CBCT) images in patients with liver metastases. In this IRB-approved retrospective single-center study 36 patients with a total of 104 liver metastases (56 % male, mean age 61.1 ± 13 years) underwent CBCT prior to TARE and follow-up imaging 6 months after therapy. Treatment response was evaluated according to RECIST version 1.1 and dichotomized into disease control (partial response/stable disease) versus disease progression (progressive disease). After target lesion segmentation, 104 radiomics features corresponding to seven different feature classes were extracted with the pyRadiomics package. After dimension reduction machine learning classifications were performed on a custom artificial neural network (ANN). Ten-fold cross validation on a previously unseen test data set was performed. The average administered cumulative activity from TARE was 1.6 Gbq (± 0.5 Gbq). At a mean follow-up of 5.9 ± 0.8 months disease control was achieved in 82 % of metastases. After dimension reduction, 15 of 104 (15 %) texture analysis features remained for further analysis. On a previously unseen set of liver metastases the Multilayer Perceptron ANN yielded a sensitivity of 94.2 %, specificity of 67.7 % and an area-under-the receiver operating characteristics curve of 0.85. Our study indicates that texture analysis-based machine learning may has potential to predict treatment response to TARE using pre-treatment CBCT images of patients with liver metastases with high accuracy.

14 June 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
AKAdrian Kobe
Adrian Kobe
LTLambros Tselikas
Lambros Tselikas
FDFrédéric Deschamps
Frédéric Deschamps
CRCharles Roux
Charles Roux
ADAlexandre Delpla
Alexandre Delpla
TBThierry De Baère
Thierry De Baère

1 December 2018 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AKAdrian Kobe
Adrian Kobe
CACelina Andreotti
Celina Andreotti
GPGilbert Puippe
Gilbert Puippe
ZRZoran Rancic
Zoran Rancic
RKReinhard Kopp
Reinhard Kopp
TPThomas Pfammatter
Thomas Pfammatter